Cooperation SeekingCreative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Elotuzumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
Elotuzumab is a humanized IgG1 monoclonal antibody that specifically binds the SLAMF7 protein. SLAMF7 is a member of the signaling lymphocyte activation molecule family and is expressed on myeloma cells. Studies have shown that Elotuzumab directly activates natural killer cells through the SLAMF7 pathway and Fc receptors, further promotes interaction with Natural Killer cells through antibody-dependent cytotoxicity (ADCC), and mediates killing of myeloma cells.
Refractory Multiple Myeloma
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.